BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36071247)

  • 21. SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
    Yu Z; Sun Y; She X; Wang Z; Chen S; Deng Z; Zhang Y; Liu Q; Liu Q; Zhao C; Li P; Liu C; Feng J; Fu H; Li G; Wu M
    J Hematol Oncol; 2017 Jun; 10(1):115. PubMed ID: 28595628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
    Durlacher CT; Li ZL; Chen XW; He ZX; Zhou SF
    Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):585-601. PubMed ID: 26999067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy.
    de Souza VB; Kawano DF
    Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129448. PubMed ID: 31676293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.
    Yang N; Wang C; Wang Z; Zona S; Lin SX; Wang X; Yan M; Zheng FM; Li SS; Xu B; Bella L; Yong JS; Lam EW; Liu Q
    Oncogene; 2017 Jun; 36(24):3428-3440. PubMed ID: 28114286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
    Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.
    Xu XL; Bao QC; Jia JM; Liu F; Guo XK; Zhang MY; Wei JL; Lu MC; Xu LL; Zhang XJ; You QD; Sun HP
    Sci Rep; 2016 Jan; 6():19004. PubMed ID: 26743233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
    Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
    J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
    Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.
    Dar AA; Belkhiri A; Ecsedy J; Zaika A; El-Rifai W
    Cancer Res; 2008 Nov; 68(21):8998-9004. PubMed ID: 18974145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
    Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
    Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
    Fiskus W; Hembruff SL; Rao R; Sharma P; Balusu R; Venkannagari S; Smith JE; Peth K; Peiper SC; Bhalla KN
    Breast Cancer Res Treat; 2012 Sep; 135(2):433-44. PubMed ID: 22825030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ID1 overexpression promotes HCC progression by amplifying the AURKA/Myc signaling pathway.
    Wu M; Zhou Y; Fei C; Chen T; Yin X; Zhang L; Ren Z
    Int J Oncol; 2020 Sep; 57(3):845-857. PubMed ID: 32705157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
    Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
    Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural anthraquinone compound emodin as a novel inhibitor of aurora A kinase: A pilot study.
    Wu FL; Chu PY; Chen GY; Wang K; Hsu WY; Ahmed A; Ma WL; Cheng WC; Wu YC; Yang JC
    Chem Biol Drug Des; 2022 Jan; 99(1):126-135. PubMed ID: 34411446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.
    Donnella HJ; Webber JT; Levin RS; Camarda R; Momcilovic O; Bayani N; Shah KN; Korkola JE; Shokat KM; Goga A; Gordan JD; Bandyopadhyay S
    Nat Chem Biol; 2018 Aug; 14(8):768-777. PubMed ID: 29942081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.
    Siggelkow W; Boehm D; Gebhard S; Battista M; Sicking I; Lebrecht A; Solbach C; Hellwig B; Rahnenführer J; Koelbl H; Gehrmann M; Marchan R; Cadenas C; Hengstler JG; Schmidt M
    BMC Cancer; 2012 Nov; 12():562. PubMed ID: 23186136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AURKA Increase the Chemosensitivity of Colon Cancer Cells to Oxaliplatin by Inhibiting the TP53-Mediated DNA Damage Response Genes.
    Shan B; Zhao R; Zhou J; Zhang M; Qi X; Wang T; Gong J; Wu Y; Zhu Y; Yang W; Zhang Y; Wang G; Li X
    Biomed Res Int; 2020; 2020():8916729. PubMed ID: 32851091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aurora-A gene is frequently amplified in basal-like breast cancer.
    Staff S; Isola J; Jumppanen M; Tanner M
    Oncol Rep; 2010 Feb; 23(2):307-12. PubMed ID: 20043089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies.
    Kaur RP; Vasudeva K; Kumar R; Munshi A
    Curr Pharm Des; 2018; 24(30):3566-3575. PubMed ID: 30255744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
    Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.